ChromaDex Corporation Reports Second Quarter 2019 Financial Results

Second Quarter 2019 Net Revenues Increased by 42% to $11.1 Million Second Quarter 2019 Highlights vs. Second Quarter 2018 ~ Strong growth in net sales to $11.1 million, significantly higher gross margins, and improved marketing efficiency year-over-year ~TRU NIAGEN net sales of $8.7 million, a 17% increase sequentially and a 134% increase year-over-year ~Global expansion continued with initial cross-border sales in China and Japan, and new ~Canadian retail distribution in Whole Foods Ontario locations ~New clinical study further demonstrated safety of sustained NIAGEN supplementation at recommended daily serving as well as statistically significant sustained blood NAD+ levels

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.